Agreement Expiration Period, Period After Date of First Commercial Sale of Product

No definition available.

Name:	rdus_AgreementExpirationPeriodPeriodAfterDateofFirstCommercialSaleofProduct
Namespace Prefix:	rdus_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the amount of additional payments to be made by the entity upon the achievement of certain development and commercialization milestones under the collaborative agreements.

+ References

No definition available.

+ Details

Name:	rdus_CollaborativeArrangementAdditionalPaymentsToBeMadeUponAchievementOfCertainDevelopmentAndCommercializationMilestones
Namespace Prefix:	rdus_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaborative Arrangement Additional Payments to be Made Upon Achievement of Certain Clinical and Regulatory Milestones

+ References

No definition available.

+ Details

Name:	rdus_CollaborativeArrangementAdditionalPaymentstobeMadeUponAchievementofCertainClinicalandRegulatoryMilestones
Namespace Prefix:	rdus_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the initial license fee under the collaborative agreements.

+ References

No definition available.

+ Details

Name:	rdus_CollaborativeArrangementInitialLicenseFee
Namespace Prefix:	rdus_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the nonrefundable payments made by the entity under the collaborative agreements.

+ References

No definition available.

+ Details

Name:	rdus_CollaborativeArrangementNonrefundablePaymentMade
Namespace Prefix:	rdus_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the period for payment of royalties after the date of the first commercial sale in such country of any product including the licensed compound.

+ References

No definition available.

+ Details

Name:	rdus_CollaborativeArrangementPeriodAfterDateOfFirstCommercialSaleOfProductForPaymentOfRoyalties
Namespace Prefix:	rdus_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the royalty as a percentage of net sales of any product by the Company or its sublicenses under the collaborative agreements.

+ References

No definition available.

+ Details

Name:	rdus_CollaborativeArrangementRoyaltyRate
Namespace Prefix:	rdus_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	rdus_CollaborativeArrangementsTypeOfAgreementAxis=rdus_EisaiMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rdus_TypeOfAgreementAxis=us-gaap_LicenseAgreementTermsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rdus_CollaborativeArrangementsTypeOfAgreementAxis=rdus_SCRASSASAndAffiliatesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rdus_TypeOfAgreementAxis=rdus_SublicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

License Agreements (Details) € in Millions	1 Months Ended		7 Months Ended	12 Months Ended
License Agreements (Details) € in Millions	Jun. 30, 2016 USD ($)	Mar. 30, 2015 USD ($)	Dec. 31, 2006 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2016 EUR (€)	Dec. 31, 2005 USD ($)
Eisai \| License Agreement
Research Agreements
Period after the date of the first commercial sale of the product for license expiration				10 years	10 years
Initial license fee paid		$ 400,000	$ 500,000
Additional payments to be made upon achievement of certain clinical and regulatory milestones	$ 22,300,000.0
Clinical Trial Services Agreement \| Ipsen
Research Agreements
Nonrefundable, non-creditable payment						$ 4,300,000
Royalty rate (as a percent)				5.00%	5.00%
Clinical Trial Services Agreement \| Ipsen \| Minimum
Research Agreements
Period after the date of the first commercial sale of the product for license expiration				10 years	10 years
Clinical Trial Services Agreement \| Ipsen \| Maximum
Research Agreements
Additional payments to be made upon achievement of certain development and commercialization milestones				$ 33,600,000	€ 32.0
Clinical Trial Services Agreement \| Ipsen \| Sublicense Agreement
Research Agreements
Period after the date of the first commercial sale of the product for license expiration				10 years	10 years
Agreement expiration period, period after date of first commercial sale of product				10 years	10 years